Treatment with Genetically Altered Viruses Targets and Destroys Ovarian Cancer in Mice
Researchers have successfully eliminated chemotherapy-resistant ovarian cancer cells in mice using a single injection of two viruses genetically combined and altered to be safe, leading to long-term survival and demonstrating a potential breakthrough treatment for women.
Yale Doc Says Lowering Recommended Age For Colon Screening is Critical Following Rise in Colorectal Cancer in Younger Patients
The United States Preventative Services taskforce has released a recommendation that colon cancer screenings start at age 45 instead of 50. It’s because more young people are being diagnosed with colon cancer. Dr. Pamela Kunz says the new recommendation is due to the staggering hike in younger cases of colon cancer.Source: WTNH News 8
Dr. Mehra Golshan Appointed Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center
Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.
Humanized Mice Lead to Breakthroughs in Blood Cancers
Humanized mice created at Yale are opening new avenues of research into cancers caused by disorders in the production of blood, such as acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). Until recently, such research was hindered because human blood stem cells are difficult to grow in cell cultures or to engraft in mice.
Dark Chemical Matter and Colon Cancer
Seven years ago, Jason Crawford, PhD, began chasing a ghost: A bacterial toxin named colibactin. He was looking for its molecular structure. He could detect bits of it, but never enough to form an entire likeness. Four years into the hunt he asked Seth Herzon, PhD, to join him. They pursued colibactin so doggedly because it is associated with up to 67 percent of all colon cancers.
The Microbiome and Cancer Treatment
Andrew Goodman, PhD, studies the abundant flora in the gut, but he initially trained in ecology and sees many parallels. He thinks of the microbiome as an ecosystem and the members of the ecosystem as bacteria. His recent research reveals that microbes are dynamic agents that should be considered in medical care.
Cancer and Obesity: The Link is Insulin
Nearly 40 percent of Americans over the age of 20 are obese, and another 32 percent are overweight. These alarming figures grow darker when combined with statistics showing that obesity is second only to smoking as a cause of preventable cancer deaths. Obesity has been linked to more than a dozen types of cancer.
From Paradox to Breakthrough
Aaron Ring, MD, PhD, was hooked by a paradox. He had been studying cytokines to understand their potential to stimulate anti-tumor immunity. Though cytokines, such as interleukin-2, have been in clinical use for decades, they have historically shown only limited effectiveness. Dr. Ring was hunting for interleukins that could deliver a specific signal to activate TILs.
Ten Years of Leadership in Immunotherapy
The last several years have been packed with revolutionary developments in immunotherapy, the decade’s biggest breakthrough in cancer treatment. Yale scientists have played leading roles in that story. Despite the tremendous progress, big challenges remain.
Scientists find many gene 'drivers' of cancer, but warn: Don't ignore 'passengers'
A massive analysis of the entire genomes of 2,658 people with 38 different types of cancer has identified mutations in 179 genes and gene regulators as “drivers” — variations in DNA sequences that lead to the development of cancer.
Kunz Named Leader of Gastrointestinal Cancers Program at Smilow Cancer Hospital and Yale Cancer Center
Pamela L. Kunz, M.D., has been appointed Leader of the Gastrointestinal Cancers Program at Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center and Director of GI Medical Oncology within the Section of Medical Oncology.
Yale Cancer Center Awards for Clinical Excellence presented during annual Conclave
Debra Brandt, D.O. and Kevin Kim, M.D. were each honored with the Yale Cancer Center (YCC) Award for Clinical Excellence at YCC’s annual Conclave on Monday, January 13. The night celebrated the accomplishments of goals set for 2019 and honored faculty and staff with clinical and research prizes.
Huntington and Parker receive new appointments at Smilow Cancer Hospital
Scott Huntington, M.D., M.P.H., assistant professor of Medicine (Hematology), has been named Medical Director for the Hematology Outpatient Program at Smilow Cancer Hospital and Terri Parker, M.D., assistant Professor of Medicine (Hematology), has been appointed the inaugural Assistant Medical Director for the Smilow Cancer Hospital Care Center in North Haven, which includes multiple myeloma and benign hematology care.
Sanft named Chief Patient Experience Officer at Smilow Cancer Hospital
Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale New Haven Hospital.
Yale Cancer Center launches Center for Community Engagement and Health Equity
Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.